Results 101 to 110 of about 27,713 (205)
Summary Objectives: The aim of the study was to evaluate antiphospholipid antibodies and antiphospholipid syndrome frequency (according to current criteria) in women with recurrent miscarriages.
Skrzypczak, Jana, Rajewski, Marcin
core
Antiphospholipid Syndrome Novel Therapies
Antiphospholipid syndrome (APS) is an autoimmune disease characterised by arterial and/or venous thrombosis, recurrent pregnancy loss, and persistently positive antiphospholipid antibodies (aPLs).
Mohamad Bittar, Imad Uthman
core
Antiphospholipid antibodies can cause recurrent thrombotic attacks in some patients. Antiphospholipid antibodies are detected in patients with autoimmune disease especially systemic lupus erythematosus, infectious, malignant and drug-induced disorders ...
Ali Rıza ODABAŞ +2 more
doaj
Neurological involvement in antiphospholipid antibodies syndrome (APS)
Antiphospholipid antibodies (aPL) have been most strongly associated with a syndrome (APS) characterized by venous and/or arterial thrombosis, thrombocytopenia, recurrent fetal losses and a variety of non-thrombotic and thrombotic neurological disorders.
AMOROSO, Antonio +5 more
core
Cross-Reactivity of Antiphospholipid Antibodies with Gut Commensal Proteins in Antiphospholipid Syndrome. [PDF]
van Mourik DJM +9 more
europepmc +1 more source
Effects of antiphospholipid antibodies in the severity and outcome of COVID-19. [PDF]
Zamani B +4 more
europepmc +1 more source
Acquired Hemophilia A (AHA) Associated With Malignancy and Antiphospholipid Antibodies: Two Case Reports With Distinct Etiologies. [PDF]
Htun NL +4 more
europepmc +1 more source
Acute Cerebellar Ataxia Associated With Antiphospholipid Antibodies in a 9-Year-Old Girl. [PDF]
Lee EH, Woo HA.
europepmc +1 more source
Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances. [PDF]
Undas A, Musiał J, Ząbczyk M.
europepmc +1 more source
Positive antiphospholipid antibodies: observation or treatment? [PDF]
Grygiel-Górniak B, Mazurkiewicz Ł.
europepmc +1 more source

